Amyris Inc. (NASDAQ:AMRS) major shareholder (Mauritius) Pte Ltd Maxwell sold 77,383 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $0.80, for a total value of $61,906.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

(Mauritius) Pte Ltd Maxwell also recently made the following trade(s):

  • On Thursday, November 17th, (Mauritius) Pte Ltd Maxwell sold 509,779 shares of Amyris stock. The shares were sold at an average price of $0.81, for a total value of $412,920.99.
  • On Tuesday, November 15th, (Mauritius) Pte Ltd Maxwell sold 648,342 shares of Amyris stock. The shares were sold at an average price of $0.81, for a total value of $525,157.02.
  • On Friday, November 11th, (Mauritius) Pte Ltd Maxwell sold 427,904 shares of Amyris stock. The shares were sold at an average price of $0.81, for a total value of $346,602.24.
  • On Tuesday, November 8th, (Mauritius) Pte Ltd Maxwell sold 333,811 shares of Amyris stock. The shares were sold at an average price of $0.82, for a total value of $273,725.02.
  • On Friday, November 4th, (Mauritius) Pte Ltd Maxwell sold 2,611,233 shares of Amyris stock. The shares were sold at an average price of $0.89, for a total value of $2,323,997.37.
  • On Monday, October 17th, (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of Amyris stock. The shares were sold at an average price of $0.83, for a total value of $1,909,000.00.

Amyris Inc. (NASDAQ:AMRS) opened at 0.7917 on Friday. The firm’s 50-day moving average price is $0.86 and its 200-day moving average price is $0.57. The company’s market cap is $208.23 million. Amyris Inc. has a 12-month low of $0.31 and a 12-month high of $1.81.

Amyris (NASDAQ:AMRS) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01. The company earned $26.50 million during the quarter, compared to analysts’ expectations of $33.61 million. The company’s revenue was up 208.1% on a year-over-year basis. During the same period last year, the firm posted ($0.23) earnings per share. Analysts expect that Amyris Inc. will post ($0.25) EPS for the current year.

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

A number of hedge funds have recently added to or reduced their stakes in AMRS. Jacobs Levy Equity Management Inc. bought a new stake in shares of Amyris during the first quarter worth $269,000. KBC Group NV boosted its stake in shares of Amyris by 330.1% in the third quarter. KBC Group NV now owns 329,101 shares of the company’s stock worth $191,000 after buying an additional 252,589 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares in the last quarter. 35.83% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have weighed in on AMRS. Zacks Investment Research lowered Amyris from a “buy” rating to a “hold” rating in a research note on Wednesday, October 19th. Singular Research restated a “buy” rating and set a $2.80 price objective on shares of Amyris in a research note on Wednesday, September 28th.

COPYRIGHT VIOLATION WARNING: “(Mauritius) Pte Ltd Maxwell Sells 77,383 Shares of Amyris Inc. (AMRS) Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2016/11/25/mauritius-pte-ltd-maxwell-sells-77383-shares-of-amyris-inc-amrs-stock.html.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS

Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.